Glucose transporter-1 inhibition overcomes imatinib resistance in gastrointestinal stromal tumor cells

Imatinib mesylate (imatinib) is the primary agent of choice used to treat gastrointestinal stromal tumors (GIST). However, drug resistance to imatinib poses a major obstacle to treatment efficacy. In addition, the relationship between imatinib resistance and glycolysis is poorly understood. Glucose...

Descripción completa

Detalles Bibliográficos
Autores principales: Shima, Takafumi, Taniguchi, Kohei, Tokumaru, Yoshihisa, Inomata, Yosuke, Arima, Jun, Lee, Sang-Woong, Takabe, Kazuaki, Yoshida, Kazuhiro, Uchiyama, Kazuhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600406/
https://www.ncbi.nlm.nih.gov/pubmed/34738628
http://dx.doi.org/10.3892/or.2021.8218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600406/
https://www.ncbi.nlm.nih.gov/pubmed/34738628
http://dx.doi.org/10.3892/or.2021.8218

Ejemplares similares